The FDA has approved Myrbetriq (mirabegron) extended-release tablets, from Astellas, for the treatment of Overactive Bladder with symptoms of urge...
In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether Myrbetriq/Betmiga (mirabegron),...
New results from clinical trials of Betmiga (mirabegron), from Astellas, support the drug's good safety and tolerability profile in treating...
The CHMP has adopted a positive opinion, recommending the granting of a marketing authorisation for Betmiga (mirabegron), from Astellas, for...